Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719327 · ClinicalTrials.gov registry record · Phase 2
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT02719327: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT02719327 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 131 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02719327, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
Interventions
- DRUG icosapent ethyl (IPE)
- OTHER gel cap placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02719327
The ClinicalTrials.gov registry entry for NCT02719327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which icosapent ethyl (IPE) is the first listed.
NCT02719327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02719327 about?
NCT02719327 is a clinical study titled "Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid". The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vasc...
What is the current status of trial NCT02719327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2017-06-08. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT02719327?
The interventions under investigation include: icosapent ethyl (IPE) (DRUG), gel cap placebo (OTHER).
Who is sponsoring clinical trial NCT02719327?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.